Qualigen Therapeutics, Inc. (QLGN) reported Q2 EPS of ($0.11), $0.05 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $1.31 million.
Qualigen Therapeutics, Inc. (QLGN) reported Q2 EPS of ($0.11), $0.05 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $1.31 million.